BiotechTube
Rhelixa

Rhelixa

Tokyo, Japan· Est.

A Japanese epigenomics leader providing multi-omics analysis services and biological age diagnostics to accelerate life science research.

rhelixa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

AI Company Overview

A Japanese epigenomics leader providing multi-omics analysis services and biological age diagnostics to accelerate life science research.

AgingNeurologyMental HealthInfectious Disease

Technology Platform

Integrated multi-omics analysis platform specializing in epigenomics (particularly DNA methylation) using next-generation sequencing and proprietary bioinformatics tools for biological age estimation and disease risk prediction.

Opportunities

Growth is driven by increasing demand for epigenetic analysis in aging research, preventive healthcare, and digital health applications, particularly in Japan's aging population and expanding research market.

Risk Factors

Key risks include dependence on the research services market, competition from larger genomic service providers, and the need to successfully translate research biomarkers into validated, reimbursable diagnostic products.

Competitive Landscape

Competes with other epigenomics and multi-omics service providers (e.g., Illumina's services, other CROs) and biological age test companies; differentiates through deep focus on DNA methylation, proprietary analysis tools (RIAS®, Epilock®), and extensive academic collaborations in Japan.

More companies in Japan →